Nervous Disorder TRIZ Cases

A once-per-cycle 0.06 mg/kg thrombomodulin infusion helps prevent and mitigate oxaliplatin-induced peripheral neuropathy with less therapy complexity.

Structural changes to quinolone analogs improve oral bioavailability, metabolic stability, and tumor killing while reducing toxicity.

Cycloserine-based ALS treatment inhibits TDP-43 aggregation, keeps the protein soluble, and helps reduce cell death linked to disease progression.

Blocking L1 reverse transcriptase with censavudine or elvucitabine downregulates IFN-I signaling to reduce age-associated inflammation.

Selective N-glycosylation weakens erythropoietic receptor binding while preserving neuroprotection and extending plasma half-life.

Combining UCBT with AAV-delivered GALC expression addresses peripheral nerve decline in Krabbe disease while improving myelination and survival.

RNAi agents silence ATXN3 mRNA through RISC cleavage, aiming to slow SCA3 progression while enabling sustained treatment effect.

Co-transplanted periventricular endothelial cells guide GABAergic interneurons, speeding brain integration and widening in vivo distribution.

microRNAs suppress STAT3, E2F6, and MAX pathways to restore adult glial progenitor cell proliferation, migration, and myelin production.

Targeted cereblon binders modify IMiD structure to boost T-cell activation across species while improving tumor and autoimmune therapy.

A polymer matrix stabilizes bupropion and dextromethorphan release, preventing ethanol dose dumping and high-fat meal food effects.

Taking an MCT emulsion 10-60 minutes before a meal raises blood ketones more than co-administration while avoiding GI side effects.

Formula I compounds improve selective Nav1.8 inhibition and pharmacokinetics, supporting treatment of pain and other channel-related diseases.

A high-purity oxytocin and V1a receptor antagonist suppresses uterine contractions quickly while enabling oral preterm labor treatment with fewer side effects.

A synergistic blend of palmitoylethanolamide, Salvia miltiorrhiza extract, and D-aspartate improves cognition with better tolerability.

Using the R-enantiomer of fenfluramine reduces seizure frequency in epilepsy and Dravet syndrome while lowering cardiotoxicity risk.

Highly purified CBD with minimal THC helps reduce Rett syndrome seizure frequency, including treatment-resistant tonic and absence seizures.

A kinetin-based approach directly modulates circadian phase, period, and amplitude to correct jet lag, shift-work disorder, and sleep disruption.

Heterobifunctional compounds recruit Tau to E3 ubiquitin ligases, enabling proteasomal degradation to reduce Tau buildup in tauopathies.

Co-formers turn psilocin into stable crystalline salts or co-crystals with better processing and tunable dissolution for psychiatric treatment.

Targets the S32A and S36A mutant sites in srIκB to distinguish it from wild-type IκB and support NF-κB pathway research and delivery.

A single-layer NAKET tablet uses a controlled-release matrix to maintain oral ketamine levels for 24-36 hours without toxic plasma spikes.

W68-targeting antibodies bind an epitope exposed only in misfolded TDP-43, enabling selective detection and blocking aggregate spread.

Conformational constraints improve 5-HT2C receptor selectivity while limiting 5-HT2A and 5-HT2B activation linked to CNS therapy side effects.

Blocking kappa opioid receptor signaling improves sleep fragmentation and daytime sleepiness in chronic pain without altering sensory pain thresholds.

Selective deuterium enrichment in ibogaine aims to relieve withdrawal and cravings rapidly while reducing side effects and addiction risk.

Anti-CGRP antibodies address migraine’s most bothersome symptoms beyond headache, improving MBS and PGIC within 1 month.

Extended-release phenylalkylamino carbamates treat ADHD while improving compliance and reducing side effects and abuse potential.

A modified GLP-1/Gcg peptide resists DPP-IV degradation to extend half-life, maintain activity, and reduce dosing frequency.

Specific cyano and cyclic hydrazine features improve JAK1/JAK2 selectivity, helping treat autoimmune disease with fewer side effects.

Combining GM-CSF and IL-2 boosts Treg numbers and activity to restore immune tolerance, reduce neuroinflammation, and slow disease progression.

Anionic polymers block Aβ-oligomer binding to cellular prion protein, offering a therapeutic route to restore synaptic plasticity and memory.

A nanoparticle composition with resveratrol or curcumin improves OSA symptom relief while avoiding costly, low-compliance mechanical treatments.

NRF2 activators target KEAP1-NRF2 signaling to reduce oxidative stress and support blood-brain barrier function in cerebral small vessel disease.

Controlled-release low-dose 5HT agonist formulations improve cognition and mood while keeping plasma levels below hallucinogenic thresholds.

Specific IL-15 mutations tune IL-15Rβ and γc binding, enabling soluble receptor-mediated activation without cell-to-cell contact.

Pooled umbilical cord blood exosomes offer a wider post-stroke treatment window, reducing infarct size, inflammation, and neural injury symptoms.

Cyclized IGFBP peptide fragments aim to deliver disease-modifying CNS and neurodevelopmental therapy with minimal side effects.

Defined growth factor conditions produce high-purity Schwann cells for authentic disease modeling, therapeutic screening, and regenerative use.

Using the miR-25802 cluster as a biomarker improves early AD diagnosis and enables targeted control of microglial inflammation.

Low-dose 5HT receptor agonist formulations improve motivation, attention, and cognitive engagement while limiting hallucinations and other side effects.

Crystalline Blarcamesine salt forms improve formulation, stability, dissolution, and bioavailability while supporting controlled pharmaceutical processing.

A modified TAT-FXN fusion polypeptide improves solubility at physiological pH, enabling higher-concentration dosing for Friedreich's ataxia.

Truncated TβRII-Fc fusion polypeptides selectively bind GDF15, TGFβ1, and TGFβ3 to block ligand-receptor signaling in disease.

D-peptides selected to bind native tau monomers stabilize folded tau and break toxic oligomers and fibrils into monomers.

Systemic FcRn inhibition blocks CNS-to-blood transcytosis of locally delivered therapeutic polypeptides, preserving tissue levels and reducing side effects.

Oxadiazole-core KCNT1 inhibitors selectively modulate sodium-activated potassium channels to treat epilepsy and related hyperexcitability disorders.

A D-amino acid C/EBPβ antagonist peptide disrupts ATF5-linked interactions to induce tumor cell death in solid tumors.

Targeted deubiquitinases restore trafficking-deficient ion channels by removing ubiquitin chains and boosting membrane protein expression.

Subcutaneous saline infusion maintains therapeutic uridine levels for rapid neuroprotection while avoiding IV hyperthermia, phlebitis, and central access.